Contact Us

Phone: 1-866-61-EISAI (1-866-61-34724)

Fax: 1-866-57-EISAI (1-866-57-34724)

Monday - Friday 8AM - 8PM ET




Legal Notice

Conditions of Use

Eisai Inc. provides this site for your personal information. You may browse or download content on this site for your personal, non-commercial use only, but thereafter such content may not be recopied, reproduced or otherwise redistributed or used. The content of this site is owned or controlled by Eisai Inc. and is protected under applicable copyright and trademark laws. All copyright and other proprietary notices contained in downloaded materials must be retained. Through your access to and use of this site, you accept, without limitation or qualification, all terms and conditions of use described throughout this site.

Jurisdiction

Although it is accessible worldwide, this site and its content are intended only for residents of the United States. Nothing in this site should be interpreted as a promotion or solicitation for any product or of any nature that is not authorized by the laws and regulations of the country where you are located.

Medical Information

This site may contain information relating to various medical conditions and their treatment. Such information is provided for educational purposes only and is not meant to be a substitute for the advice of a physician or other healthcare professional. You should not use this information for diagnosing or treating a health problem or disease. In order for you to make intelligent healthcare decisions, you should always consult with your physician or other healthcare provider for your personal medical needs.

Some areas of this site may ask you to submit personally identifiable information in order for you to benefit from the specified features (such as newsletter subscriptions, tips/pointers, order processing, or resume submission) or to participate in a particular activity (such as sweepstakes or other promotions). You will be informed what information is required and what information is optional.

Privacy

Any "personally identifiable" information in electronic communications to this site is governed by and subject to the site's Privacy Policy. By "personally identifiable" information, we mean data that are unique to an individual, such as a name, address, social security number or telephone number.

Unsolicited Submissions

Under no circumstances should you use this site or any of the fax or mailing addresses listed on this site to send Eisai Inc. confidential or proprietary information. Your unsolicited communications to us, including any ideas, inventions, concepts, techniques, know-how, proposals, data, questions, comments or similar such materials and information, other than the personal information described above, will be treated as non-confidential and non-proprietary information. Eisai reserve the right to use any such communications, including without limitation any ideas, inventions, concepts, know-how, processes or techniques disclosed therein for any purpose whatsoever, including by reproducing, disclosing and distributing such information or otherwise using such information in connection with the development, manufacture and marketing of products or services. You shall be responsible for the content and information contained in any communications sent or submitted by you to this site or otherwise to the owners of this site, including for the truthfulness and accuracy of such content and information.

Links to Other Sites

As a convenience, from time to time www.EisaiReimbursement.com may contain certain links or references to other sites that we think may be useful or of interest to you. Eisai does not control, endorses, promote or has any affiliation with any other site unless expressly stated herein or on such site. The owners of this site therefore have no responsibility for the content, accuracy or any other aspect of the information contained on such linked sites. Eisai will not be liable for any damages or injury arising from your access to such sites or content. The trademarks, service marks, trade names, trade dress and products in this site are protected in the United States and internationally. Nothing contained in this site shall be construed as conferring on you any license or right under any copyright, patent, trademark or trade name or under any other proprietary rights of Eisai Inc. or any third party, whether by implication, estoppel or otherwise. No use may be made by you of any of these without the prior written authorization of the owners of this site or of the respective proprietary rights, as applicable, except to identify products or services of the owners.

Warranties

Eisai does not make any representations or warranties as to the timeliness, availability, accuracy or completeness of any information contained in this site. Like any printed materials, the information provided in this site may become outdated over time. Eisai undertake no obligation to correct or update any content or information on this site. Eisai may make improvements and/or changes in the products and/or services described in this content and information at any time without notice and reserve the right to alter or delete content and information in the site at any time. All information on this site is provided "AS IS," without any warranties, including but not limited to IMPLIED WARRANTIES OF MERCHANTABILITY, FITNESS FOR A PARTICULAR PURPOSE, OR NON-INFRINGEMENT, ALL OF WHICH ARE EXPRESSLY DISCLAIMED. All visitors to www.EisaiReimbursement.com agree that all access to and use of this site and its content are at their own risk. None of Eisai any affiliate of either of them, or any party involved in creating, producing or delivering this site will be liable for any injury or any direct, indirect, special, exemplary, incidental, consequential, punitive or other damages arising out of access to, use of or inability to use www.EisaiReimbursement.com or any errors or omissions in the content thereof or from reliance on any information on this site, even if Eisai is informed of the possibility of such damages.

Trademarks

All product names, trademarks, logos and service marks (collectively referred to as "Trademarks") displayed on this site are the property of Eisai their respective affiliates, related companies, licensors or business partners. The use or misuse of these Trademarks or any other materials, except as permitted herein, is expressly prohibited and may be in violation of the laws of copyright, trademark, privacy, publicity, slander, libel and communications. Please be advised that each of Eisai (and their respective affiliates) actively and aggressively enforces its intellectual property rights to the fullest extent of the law.

Images of people or places displayed on this site are either the property of, or used with permission by, Eisai. The use of these images by you is prohibited unless specifically permitted by the terms and conditions of this site. Unauthorized use of the images may violate the laws of copyright, trademark, privacy, publicity and communications.

Indication

ONTAK® (denileukin difitox) is indicated for the treatment of patients with persistent or recurrent cutaneous T-cell lymphoma whose malignant cells express the CD25 component of the IL–2 receptor.

Important Safety Information

The following adverse reactions have been reported:
  • Serious and fatal infusion reactions. Administer ONTAK® in a facility equipped and staffed for cardiopulmonary resuscitation. Immediately stop and permanently discontinue ONTAK® for serious infusion reactions.
  • Capillary leak syndrome resulting in death. Monitor weight, edema, blood pressure and serum albumin levels prior to and during ONTAK® treatment.
  • Loss of visual acuity and color vision.

Infusion Reactions

Infusion reactions, defined as symptoms occurring within 24 hours of infusion and resolving within 48 hours of the last infusion in that course, were reported in 70.5% of 234 ONTAK®-treated patients across 3 clinical studies. Serious infusion reactions were reported in 8.1% of patients. There have been post-marketing reports of infusion reactions resulting in death. For patients completing at least 4 courses of ONTAK® treatment in a placebo-controlled trial, the incidence of infusion reactions was lower in the third and fourth cycles as compared to the first and second cycles of ONTAK®.

Capillary leak syndrome

Capillary leak syndrome was defined as the occurrence of at least 2 of the following 3 symptoms (hypotension, edema, serum albumin < 3.0 g/dL) at any time during ONTAK® therapy. These symptoms were not required to occur simultaneously to be characterized as capillary leak syndrome. As defined, capillary leak syndrome was reported in 32.5% (76/234) of ONTAK®-treated patients in clinical studies; one-third required hospitalization or medical intervention to prevent hospitalization. There are post-marketing reports of capillary leak syndrome resulting in death. The onset of symptoms in patients with capillary leak syndrome may be delayed, occurring up to 2 weeks following infusion. Symptoms may persist or worsen after the cessation of ONTAK®.

Regularly assess patients for weight gain, new onset or worsening edema and hypotension (including orthostatic changes). Monitor serum albumin levels prior to each course of therapy and more often as clinically indicated. Withhold ONTAK® for serum albumin levels less than 3 g/dL.

Visual loss

Loss of visual acuity, usually with loss of color vision, with or without retinal pigment mottling has been reported following administration of ONTAK®. Recovery was reported in some of the affected patients; however, most patients reported persistent visual impairment.

Hepatobilary Disorders

Increase in ALT/AST from baseline occurred in 84% of ONTAK®-treated patients. The majority of these elevations occurred during either the first or second cycle, resolved without medical intervention, and did not require discontinuation of ONTAK®.

Pregnancy and Lactation

ONTAK® should be given to a pregnant woman only if clearly needed and should not be used in women who are nursing.

Most Common Adverse Reactions

In clinical studies (n=234), the most common adverse reactions in ONTAK®-treated patients (≥20%) were pyrexia, nausea, fatigue, rigors, vomiting, diarrhea, headache, peripheral edema, cough, dyspnea and pruritus. The most common serious adverse reactions were capillary leak syndrome (11.1%), infusion reactions (8.1%), and visual changes including loss of visual acuity (4%). ONTAK® was discontinued in 28.2% of patients due to adverse reactions.

Please see the ONTAK® full Prescribing Information including Boxed WARNINGS and additional important safety information.



Eisai cannot guarantee payment of any claim. Coding, coverage, and reimbursement may vary significantly by payor, plan, patient, and setting of care. Actual coverage and reimbursement decisions are made by individual payors following the receipt of claims. For additional information, customers should consult with their payors for all relevant coding, reimbursement, and coverage requirements. It is the sole responsibility of the provider to select the proper code and ensure the accuracy of all claims used in seeking reimbursement. All services must be medically appropriate and properly supported in the patient medical record.

This information is intended for use by our healthcare professionals in the United States only. Eisai Inc. recognizes the Internet is a global communications medium; however, laws, regulatory requirements and medical practices for pharmaceutical products vary from country to country. The Prescribing Information included here is not appropriate for use outside the United States. This site contains information about products that may have different product labeling in different countries.

ONTAK® is a registered trademark of Eisai Inc.

CORP74DR7 ©2012 Eisai Inc. All rights reserved.

This site was last modified on : December 19, 2011 at 5:45pm ET